Ades 1987.

Study characteristics
Methods	Randomised clinical trial at a single site in the United States
Participants	36 participants meeting at least 2 of 3 criteria for diagnosis of AMI: myocardial ischaemic pain lasting 30 minutes or longer, an increase in serum creatine kinase levels to twice the normal range with MB isoenzyme present, appearance of new Q waves or evolutionary ST changes, younger than 75 years and diagnosed Male:female = 30:6 Mean age = 53 years Exclusion criteria: age 75 years or older, post‐AMI infarction chest pain in the 4 days before treadmill testing, clinically overt heart failure (raies, third heart sound), severe obstructive lung disease, long‐term beta‐adrenergic blockade for systemic hypertension or exercise‐limiting peripheral vascular disease
Interventions	Experimental group: metoprolol (100 mg 1 tablet twice daily for a minimum of 5 doses before initial submaximal treadmill test (performed around 8 days after AMI)) Control group: matching placebo Co‐intervention: other anti‐ischaemic medications, such as nitrates or calcium antagonist drugs, were allowed but were kept steady for the duration of the protocol. Nine patients were taking calcium antagonist drugs, 16 nitrates, and 3 digitalis Excluded medication: not described
Outcomes	Outcomes: exercise parameters, rest haemodynamic variables Time points reported: Day 6
Notes	Study author was contacted at Philip.Ades@uvmhealth.org on 20‐06‐2017. No response was received Study was described as a double‐blinded, placebo‐controlled, cross‐over trial. However, It did not report how many participants were included in each group, and no useful data could be extracted from this trial Study was funded by Geigy, Inc., which provided study medication and matching placebo medication
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	This was a double‐blinded, placebo‐controlled, cross‐over trial
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	This was a double‐blinded, placebo‐controlled, cross‐over trial
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	High risk	No protocol could be found, and mortality and SAEs were not reported
Other bias	Low risk	No other biases were found